How Doctors Choose Medications to Treat Type 2 Diabetes

OBJECTIVE—Glycemic control remains suboptimal despite the wide range of available medications. More effective medication prescription might result in better control. However, the process by which physicians choose glucose-lowering medicines is poorly understood. We sought to study the means by which physicians choose medications for type 2 diabetic patients. RESEARCH DESIGN AND METHODS—We surveyed 886 physician members of either the Society of General Internal Medicine (academic generalists, response rate 30%) or the American Diabetes Association (specialists, response rate 23%) currently managing patients with type 2 diabetes. Respondents weighed the importance of 15 patient, physician, and nonclinical factors when deciding which medications to prescribe for type 2 diabetic subjects at each of three management stages (initiation, use of second-line oral agents, and insulin). RESULTS—Respondents reported using a median of five major considerations (interquartile range 4–6) at each stage. Frequently cited major considerations included overall assessment of the patient's health/comorbidity, A1C level, and patient's adherence behavior but not expert guidelines/hospital algorithms or patient age. For insulin initiation, academic generalists placed greater emphasis on patient adherence (76 vs. 60% of specialists, P < 0.001). These generalists also identified patient fear of injections (68%) and patient desire to prolong noninsulin therapy (68%) as major insulin barriers. Overall, qualitative factors (e.g., adherence, motivation, overall health assessment) were somewhat more highly considered than quantitative factors (e.g., A1C, age, weight) with mean aggregate scores of 7.3 vs. 6.9 on a scale of 0–10, P < 0.001. CONCLUSIONS—The physicians in our survey considered a wide range of qualitative and quantitative factors when making medication choices for hyperglycemia management. The apparent complexity of the medication choice process contrasts with current evidence-based treatment guidelines.

[1]  Resistance to Insulin Therapy Among Patients and Providers Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study , 2005 .

[2]  M. Chin,et al.  Specialty differences in the care of older patients with diabetes. , 2000, Medical care.

[3]  M. Chin,et al.  Variations in the care of elderly persons with diabetes among endocrinologists, general internists, and geriatricians. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[5]  Health care resource utilization associated with a diabetes center and a general medicine clinic , 2007, Journal of General Internal Medicine.

[6]  Carl van Walraven,et al.  Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? , 2005, Diabetes care.

[7]  Richard W Grant,et al.  Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. , 2005, Diabetes care.

[8]  D. Nathan Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes , 2007, Diabetes Care.

[9]  P. Lyne,et al.  Understanding Why People with Type 1 Diabetes Do Not Attend for Specialist Advice: A Qualitative Analysis of the Views of People with Insulin-dependent Diabetes Who Do Not Attend Diabetes Clinic , 2005, Journal of health psychology.

[10]  A. Mooradian,et al.  Narrative Review: A Rational Approach to Starting Insulin Therapy , 2006, Annals of Internal Medicine.

[11]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[12]  Jay R. Desai,et al.  Randomized trial of quality improvement intervention to improve diabetes care in primary care settings. , 2005, Diabetes care.

[13]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[14]  S. Saydah,et al.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. , 2004, JAMA.

[15]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[16]  P. Odegard,et al.  Inhaled Insulin: Exubera , 2005, The Annals of pharmacotherapy.

[17]  D. Grobbee,et al.  Initiation of glucose‐lowering therapy in Type 2 diabetes mellitus patients in general practice , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[18]  R. Segal,et al.  Drug Choice as a Problem-solving Process , 1985, Medical care.

[19]  A. Farmer,et al.  Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[20]  P. Savage,et al.  Antidiabetic treatment trends in a cohort of elderly people with diabetes. The cardiovascular health study, 1989-1997. , 1999, Diabetes care.

[21]  H. Lebovitz Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[22]  L. Phillips,et al.  Diabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocols. , 1999, Diabetes care.

[23]  B. Snively,et al.  Primary and specialty medical care among ethnically diverse, older rural adults with type 2 diabetes: the ELDER Diabetes Study. , 2005, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

[24]  Z. Bloomgarden Gut-derived incretin hormones and new therapeutic approaches. , 2004, Diabetes care.

[25]  M. Engelgau,et al.  A Diabetes Report Card for the United States: Quality of Care in the 1990s , 2002, Annals of Internal Medicine.

[26]  G. Barnett,et al.  Randomized controlled trial of an informatics-based intervention to increase statin prescription for secondary prevention of coronary disease , 2007, Journal of General Internal Medicine.

[27]  D. Singer,et al.  Trends in complexity of diabetes care in the United States from 1991 to 2000. , 2004, Archives of internal medicine.

[28]  P. Cryer Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes , 2007, Diabetes Care.

[29]  D. Marrero,et al.  Impact of a program to improve adherence to diabetes guidelines by primary care physicians. , 2002, Diabetes care.

[30]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[31]  D. Berlowitz,et al.  Differential Adoption of Pharmacotherapy Recommendations for Type 2 Diabetes by Generalists and Specialists , 2003, Medical care research and review : MCRR.

[32]  J. Wogen,et al.  Utilization of oral hypoglycemic agents in a drug-insured U.S. population. , 2001, Diabetes care.